DOV-216,303

DOV 216,303 is an experimental antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004;^[1] Merck and DOV terminated their relationship in December 2006.^{[2]: 12 [3]}

Legal status

• US: Investigational New Drug

CAS Number

• 66504-40-3 ^N

PubChem CID

• 9795276

ChemSpider

• 7971043 ^N

Quick facts Legal status, Identifiers ...

DOV-216,303

Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
CAS Number	66504-40-3 N
PubChem CID	9795276
ChemSpider	7971043 N
UNII	5W2YA6F455
ChEMBL	ChEMBL528995 N
Chemical and physical data
Formula	C11H11Cl2N
Molar mass	228.12 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1C2C1(CNC2)C3=CC(=C(C=C3)Cl)Cl
InChI InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2 N Key:BSMNRYCSBFHEMQ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Close

It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).^[4] It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC₅₀ values for SERT, NET, and DAT are K_i 14 nM, 20 nM, and 78 nM, respectively.^[4]

As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.^[2]: 6

In a mouse model, DOV-216,303 has shown the ability to promote recovery after spinal cord contusion.^[5]